Funding of Innovative Medicine Welcomed

Medicines New Zealand Media Release, 14 June 2011

PHARMAC’s decision to fund a new type of innovative anti-blood clotting treatment has been welcomed by Medicines New Zealand.

“This treatment is expected to have significant benefits for patients who require anti coagulant therapy and is an example of the way in which innovative medicines can have major impacts on peoples’ quality of life,” Medicines New Zealand General Manager Kevin Sheehy says.

“The decision to fund this genuinely innovative medicine has been prompt and is made possible by the recent announcement from the Health Minister, Tony Ryall, of additional funding for PHARMAC.”

“We congratulate the company that created this innovative product and worked with PHARMAC to make it available to New Zealanders. As a member of Medicines New Zealand we are immensely proud of their contribution to improving health outcomes.”

“We also congratulate PHARMAC on the ability to respond rapidly to this opportunity for improving health outcomes for New Zealanders through investing in innovative medicine. We hope that this new responsiveness continues so that Kiwis are assured of having early access to the many improved treatments which are available now and in the future.”

ENDS

© Scoop Media